Pfizer secures China nod for obesity drug as generics loom

China has approved a new obesity treatment from Pfizer Inc., heightening competition in a market poised to become even more ...
BioSpace

Pfizer’s Ibrance Heir Reduces Risk of Death in Phase 2 Breast Cancer Test

Pfizer has a lofty goal for the CDK4 inhibitor atirmociclib, the New York pharma’s answer to Ibrance’s loss of patent protection next year. In 2025, Ibrance led Pfizer’s oncology portfolio with $1.04 ...
BioPharma Dive

Pfizer’s Ibrance successor moves forward with new study data

The drug, which one analyst described as a “critical” part of Pfizer’s oncology strategy, represents a possible improvement upon Ibrance and other, similar breast cancer medicines from Eli Lilly and ...

China approves Pfizer GLP-1 drug for weight loss

By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...

Should You Avoid Pfizer? Here's the Key Risk to Watch

Pfizer has reached a turning point.
Texarkana Gazette

Pfizer to make generic Viagra pill available beginning Monday

TRENTON, N.J.-The little blue pill that's helped millions of men in the bedroom is turning white. Drugmaker Pfizer is launching its own cheaper generic version of Viagra rather than lose most sales ...

Pfizer, Teva lose bid to disqualify ex-prosecutor in generic drug price‑fixing case

Pfizer , Teva and other major drugmakers have failed to persuade a federal judge to disqualify a former prosecutor who is representing private health insurers suing the ​companies after he spearheaded ...